相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting
Alejandro A. Gru et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2023)
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
Youn H. Kim et al.
EUROPEAN JOURNAL OF CANCER (2021)
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma
Nicholas C. Richardson et al.
ONCOLOGIST (2019)
Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
Paul G. Rubinstein et al.
BLOOD (2019)
Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma
Ziba Rahbar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD (2018)
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
Nancy L. Bartlett et al.
LEUKEMIA & LYMPHOMA (2017)
BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION
Y.H. Kim et al.
HEMATOLOGICAL ONCOLOGY (2017)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
Brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by PD1 inhibition in vivo
Anthony T. Cao et al.
CANCER RESEARCH (2017)
CD30 Expression by B and T Cells A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified
Arantza Onaindia et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
Fu Li et al.
CANCER RESEARCH (2016)
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen et al.
BLOOD (2015)
Brentuximab vedotin-mediated immunogenic cell death
Shyra J. Gardai et al.
CANCER RESEARCH (2015)
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
Youn H. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
Madeleine Duvic et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels
Celine Bossard et al.
BLOOD (2014)
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Steven M. Horwitz et al.
BLOOD (2014)
CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia
Graham W. Slack et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Relationship between in vivo antitumor activity of ADC and payload release in preclinical models
Fu Li et al.
CANCER RESEARCH (2014)
Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Philipp Mueller et al.
CANCER IMMUNOLOGY RESEARCH (2014)
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
Shimin Hu et al.
BLOOD (2013)
CD30 expression in peripheral T-cell lymphomas
Elena Sabattini et al.
HAEMATOLOGICA (2013)
Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases
German Campuzano-Zuluaga et al.
LEUKEMIA & LYMPHOMA (2013)
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley et al.
CLINICAL CANCER RESEARCH (2010)
CD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides
James T. Edinger et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Ezogelin Oflazoglu et al.
BLOOD (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5
HP Hansen et al.
FASEB JOURNAL (2004)
CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses
KW Chan et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
